Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Portal Hypertension
What are your clinical considerations to pursue an automated-low-flow ascites (ALFA) pump for a patient with refractory ascites?
Answer from: at Academic Institution
A patient whose ascites is difficult to control and has contra-indications for TIPS.
Sign In
or
Register
to read more
Answer from: at Academic Institution
A patient who is not a liver transplant candidate and has a contraindication to TIPS can be considered for the ALFA pump.
Sign In
or
Register
to read more
29791
30245
Related Questions
Who would be the right candidate in which TIPS placement would reduce portal hypertension to allow for a previously unattainable procedure?
What clinical scenario would you favor NOT using terlipressin for the management of HRS if there were no notable contraindications for its initiation?
In patients who meet Baveno VII NIT criteria for CSPH and are candidates for NSBB to prevent decompensation, when (if ever) do you still perform screening endoscopy before starting NSBB, and what specific findings would change your management?
How do you use IVC caliber and collapsibility to guide decisions about diuresis?
How does the presence of porto-mesenteric vein thrombosis impact a patient's transplant candidacy?
What clinical evidence do you find most favorable of a positive response post-liver transplant for patients with portopulmonary hypertension?
How do you balance the need for diuretics from a volume perspective (Ex: ascites, edema) in decompensated cirrhotic patients and progressive renal dysfunction?
What is your approach to the management of post-TIPS hepatic encephalopathy?
How do you decide between empiric carvedilol versus obtaining HVPG to confirm CSPH when noninvasive markers suggest CSPH but there is limited hemodynamic/renal reserve (borderline MAP and/or CKD)?
What factors do you consider when deciding to treat IgA nephropathy with immunosuppression in a patient with cirrhosis, given the possibility that IgA nephropathy could be secondary to cirrhosis?